CAMCEVI, which was approved by the FDA in May 2021 and commercially launched in the U.S. in March 2022, has allowed Accord to significantly grow its share of the advanced prostate cancer market. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results